Live News Categoriesmarket

INVIOS (INVIOS) News

Follow INVIOS (INVIOS) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 1 public stories across 1 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.

Symbol INVIOS Asset market Sector Markets 90 days 1 Updated Oct 15, 2026, 08:06 AM UTC Open live news feed

M invIOs Reports Phase 1 APN401 Data in 17 Patients APN401 was well tolerated in 17 patients with advanced solid tumors, with no dose-limiting toxicities. invIOs selected 4.5×10⁷ PBMCs/kg as the recommended Phase 2 dose; disease stabilization occurred in 5 of 10 RECIST-ev EQUITY | Oct 15, 2026, 08:06 AM UTC